DE69406664T2 - Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 - Google Patents

Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6

Info

Publication number
DE69406664T2
DE69406664T2 DE69406664T DE69406664T DE69406664T2 DE 69406664 T2 DE69406664 T2 DE 69406664T2 DE 69406664 T DE69406664 T DE 69406664T DE 69406664 T DE69406664 T DE 69406664T DE 69406664 T2 DE69406664 T2 DE 69406664T2
Authority
DE
Germany
Prior art keywords
cell
epitope
cd44v6
cells
hermes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69406664T
Other languages
English (en)
Other versions
DE69406664D1 (de
Inventor
Sirpa Jalkanen
Marko Salmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22141703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69406664(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of DE69406664D1 publication Critical patent/DE69406664D1/de
Publication of DE69406664T2 publication Critical patent/DE69406664T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69406664T 1993-06-18 1994-06-16 Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 Expired - Fee Related DE69406664T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7806393A 1993-06-18 1993-06-18
PCT/FI1994/000264 WO1995000658A1 (en) 1993-06-18 1994-06-16 COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6

Publications (2)

Publication Number Publication Date
DE69406664D1 DE69406664D1 (de) 1997-12-11
DE69406664T2 true DE69406664T2 (de) 1998-06-04

Family

ID=22141703

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69406664T Expired - Fee Related DE69406664T2 (de) 1993-06-18 1994-06-16 Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6

Country Status (13)

Country Link
US (1) US5616468A (de)
EP (1) EP0703989B1 (de)
JP (1) JPH08511419A (de)
AT (1) ATE159953T1 (de)
AU (1) AU678487B2 (de)
CA (1) CA2165461A1 (de)
DE (1) DE69406664T2 (de)
DK (1) DK0703989T3 (de)
ES (1) ES2110764T3 (de)
GR (1) GR3025759T3 (de)
IL (1) IL110070A0 (de)
WO (1) WO1995000658A1 (de)
ZA (1) ZA944383B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134982A1 (de) * 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
EP0656906B1 (de) * 1992-06-09 1999-09-08 Oy Biotie Therapies Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
CN102504025B (zh) * 2004-03-10 2015-10-21 克赖顿大学 雌激素受体和使用方法
WO2005095987A2 (en) * 2004-03-26 2005-10-13 University Of Miami Salivary soluble cd44: a molecular marker for head and neck cancer
EP2041299A4 (de) * 2006-07-14 2010-01-13 Aviva Biosciences Corp Verfahren und zusammensetzungen für den nachweis seltener zellen aus einer biologischen probe
US20080057505A1 (en) * 2006-07-14 2008-03-06 Ping Lin Methods and compositions for detecting rare cells from a biological sample
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
MX2013010910A (es) * 2011-03-24 2014-03-27 Neurim Pharma 1991 Peptidos neuroprotectores.
RU2017104284A (ru) 2014-07-15 2018-08-15 Йиссум Рисеч Девелопмент Компани Оф Зе Хебрю Юниверсити Оф Джерусалем Лтд. Выделенные полипептиды cd44 и их применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014510A1 (de) 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE4134982A1 (de) 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Also Published As

Publication number Publication date
CA2165461A1 (en) 1995-01-05
US5616468A (en) 1997-04-01
WO1995000658A1 (en) 1995-01-05
DK0703989T3 (da) 1998-02-09
GR3025759T3 (en) 1998-03-31
IL110070A0 (en) 1994-10-07
ZA944383B (en) 1995-03-03
JPH08511419A (ja) 1996-12-03
AU6972694A (en) 1995-01-17
ES2110764T3 (es) 1998-02-16
EP0703989B1 (de) 1997-11-05
EP0703989A1 (de) 1996-04-03
ATE159953T1 (de) 1997-11-15
DE69406664D1 (de) 1997-12-11
AU678487B2 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
DE69406664T2 (de) Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
Meigel et al. Dermal architecture and collagen type distribution
Bukovský et al. The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube.
Fogel et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma
Weiss et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function
Sasaki et al. Expression and distribution of laminin α1 and α2 chains in embryonic and adult mouse tissues: an immunochemical approach
Sappino et al. Smooth muscle differentiation in scleroderma fibroblastic cells.
Purkis et al. Antibody markers of basal cells in complex epithelia
Sheikh et al. Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor
Natali et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions
Matsuura et al. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma.
Heyderman et al. A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2
Sers et al. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread
Chaubal et al. CD34 immunoreactivity in nervous system tumors
Hormia et al. Expression of cytokeratins in odontogenic jaw cysts: monoclonal antibodies reveal distinct variation between different cyst types
Hamilton et al. Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen
Bordessoule et al. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67
Cagnano et al. Expression of ligands to NKp46 in benign and malignant melanocytes
Adachi et al. Microvascular architecture of early gastric carcinoma. Microvascular–histopathologic correlates
Posnett et al. A membrane antigen (HC1) selectively present on hairy cell leukemia cells, endothelial cells, and epidermal basal cells.
Tiitta et al. Tenascin in inflammatory conditions and neoplasms of the urinary bladder
Gilcrease et al. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas
Georgolios et al. THE ROLE OF CD�� ADHESION MOLECULE IN ORAL CAVITY CANCER
Castagna et al. Mammary cancer antigen recognized by monoclonal antibody B72. 3 in apocrine metaplasia of the human breast
Rudland et al. Characterization of human mammary cell types in primary culture: immunofluorescent and immunocytochemical indicators of cellular heterogeneity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee